An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies | Project

Affiliate of Centre for Extracellular Vesicle Nanomedicine: Centre for Extracellular Vesicle Nanomedicine; Faculty of Health, Medicine and Behavioural Sciences

Honorary Professor: Mater Research Institute-UQ; Faculty of Health, Medicine and Behavioural Sciences

Maher Gandhi

Principal Research Fellow: Frazer Institute; Faculty of Health, Medicine and Behavioural Sciences

Colm Keane

ATH - Associate Professor: PA Southside Clinical Unit; Faculty of Health, Medicine and Behavioural Sciences

Peter Mollee

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies (2018-2025)